This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

28 Aug 2017

Berg and AstraZeneca collaborate to identify new therapeutic targets to treat neurological disorders

Collaboration to focus on a disease target in Parkinson's disease with Berg's Interrogative Biology technology.

BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, has announced a research collaboration with AstraZeneca to identify and evaluate novel targets and therapeutics to treat neurological disorders such as Parkinson's disease.

AstraZeneca will initially provide Berg with its curated library of central nervous system (CNS) optimized fragments. Berg will employ AstraZeneca's fragment library to assist in discovering drug candidates for therapeutic development.

"For the past decade, Berg has been at the forefront of using artificial intelligence for drug discovery, and we're excited to partner with AstraZeneca, which has been an industry leader in discovering and developing therapeutics to improve patient care in neuroscience," says Niven R. Narain, Berg Co-Founder, President and CEO. "Parkinson's disease is a devastating progressive disorder, and we're proud to collaborate with AstraZeneca to find new approaches for treating Parkinson's patients and exploring therapeutic targets for additional neurological diseases."

"AstraZeneca is committed to advancing therapies in neuroscience. Through this research collaboration, we can approach drug discovery in an innovative new way using Berg's artificial intelligence platform," said Dr Iain Chessell, Head of Neuroscience at AstraZeneca. "We look forward to collaborating with Berg to help us identify new therapeutic targets that can potentially benefit patients with neurological disorders, an area of significant unmet medical need."

Berg's Parkinson's target was discovered through the Berg Interrogative Biology technology which relies on a "back to biology" approach. Berg's drug-discovery efforts originate with patient biology. Samples are collected from diseased and healthy patients, and subjected to omics analysis that includes examination of the genome, proteome, lipidome and metabolome. The data is then combined with patient clinical information and analysed by Berg's proprietary artificial intelligence analytics platform, with the goal of advancing potential assets into the clinic.

This process can produce trillions of data points from a single sample. Berg's current clinical pipeline consists of therapeutics as well as companion and disease diagnostics that support clinical development in the areas of oncology, neurology and endocrinology.

Related News